Cardio-Oncology Spotlight: BTK Inhibitors and CV Risks

With the rapid increase in the use of BTK inhibitors managing CV risk is increasingly challenging and important. In this episode leading experts from the University of Pennsylvania medical school guide us through some of these complexities. Watch to the full webinar here: https://www.radcliffecardiology.com/webinars/managing-cv-risk-patients-cll Dr. Emily Tomasulo is a Hematologist/Oncologist who specializes in B-cell lymphoma and cellular therapy at Pennsylvania Hospital and the Hospital of the University of Pennsylvania. She sits on ECOG-ACRIN Leukemia Committee and her research and clinical interests focus on the use of targeted and cellular therapies in B-cell malignancies with particular attention to cardiovascular adverse effects.Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and Medical Director of the Thalheimer Center for Cardio-Oncology. He trained at Yale University, Johns Hopkins University, and Massachusetts General Hospital. His clinical and research interests focus on arrhythmic complications of cancer therapies. He currently serves as President of the International Cardio-Oncology Society (IC-OS).

On this episode of Heart to Heart patient advocate Lee Ramsey helps us appreciate the value of having a cardiologist engaged in both the assessment and management of CV complications before, during, and after cancer treatment.

Dr. Abuzaid received his degree in medicine from Ain Shams University, Faculty of Medicine, Cairo, Egypt, 2006. He completed his residency in Internal Medicine at Creighton University, Omaha, Nebraska in 2015 followed by a Fellowship in Cardiovascular Disease, Sidney Kimmel Medical College at Thomas Jefferson University, Christiana Care Health System, Newark, Delaware, 2018 and a Fellowship in Advanced echocardiography and advanced Cardiovascular Imaging, University of California, San Francisco, CA, (UCSF) 2019.

Dr. Skouri is President of the IC-OS chapter of the United Arab Emirates. He specializes in advanced heart failure including “Assist devices”, heart transplantation, cardio-oncology, pulmonary hypertension, and cardiac amyloidosis. He has been an Associate Professor of Clinical Medicine at AUBMC in Lebanon for the last 5 years and has published more than 55 research papers, consensus documents, and position papers that directly contribute to the advancement of cardiology and Heart Failure.

Dr. Armstrong is a member, St. Jude Faculty, Chair, Department of Epidemiology and Cancer Control, Co-Leader, Cancer Control & Survivorship Program and Endowed Chair in Epidemiology & Cancer Control, St Jude's Research Hospital.

Dr. Singh has been instrumental in starting the Diabetic Cardio–metabolic unit at Netcare Umhlanga Hospital, Durban and instrumental in starting the first Cardio–oncology Unit in South Africa, and in fact, the continent of Africa. He is President of the Cardio–oncology Society of Southern Africa (COSOSA). This is the first Cardio–oncology Society in South Africa and in fact, Southern Africa. He is also President of the S. Africa chapter of the International Cardio–oncology Society (ICOS).

Dr. Alexia Oliver opened our 2025 Global Summit sharing her harrowing account of being on the brink of completing her medical training only to discover she had an aggressive lymphoma. Her treatment was followed by chemotherapy-induced heart failure so severe she was placed on the transplant list, yet she slowly recovered against all expectations. After additional setbacks—including bilateral hip replacements—she returned to medical school with a renewed sense of purpose, grounded in the conviction that having a “why” makes survival possible. She embodies the reason our community exists, you won't want to miss this episode.

Dr. James Wilson is a consultant clinical oncologist in the UK who specializes in lung and skin cancers. He works at several London hospitals, including the London Clinic, The Cromwell Hospital, and Leaders in Oncology Care (LOC), and also has an NHS base at University College London Hospital (UCLH). His expertise includes treatments like advanced radiotherapy (such as SABR and CyberKnife), chemotherapy, and immunotherapy, and he is involved in research and clinical trials.

Francesca Ossani survived breast cancer and cardiovascular complications of her cancer therapy but discovered beauty and hope along the way. She discovered the value of collaborative medical care and the hope of sharing the journey with others. She now continues to spread hope and joy in her volunteer work at a pediatric cancer center. Join us as we hear of her remarkable story of hope and joy in the face of incredible challenges.

As part of our 2025 Board Review Course Dr. Mahmood provides insights into the contemporary state of our understanding of CAR T therapies, their CV risk, and management. You can purchase the complete set of review course videos at the link below. This includes modules covering the Management & Detection of Cardiac Dysfunction, Toxicities of Traditional Therapies, Hematology, and Immunotherapy.https://members.ic-os.org/store/viewproduct.aspx?id=26378193